SlideShare a Scribd company logo
1 of 23
THE STANFORD-CANCER GENOME ATLAS PORTAL:
A WEB/MOBILE NAVIGATION INTERFACE FOR EXPLORING THE
CLINICAL ASSOCIATIONS OF CANCER DRIVERS
Tutorial: How to navigate the web portal
Three ways of looking TCGA data
What are the clinically relevant genes/miRs/proteins?
• By name of genes, miRs or proteins
• By cancer type
• By clinical parameters
Profiling by clinical parameters:
What is the difference in genetic/proteomic changes
between classes in a clinical parameter in a certain
cancer?
Two hit hypothesis test:
Do the two genetic/proteomic changes occur together
or not?
I
II
III
I. Checking what clinical parameters are associated with
genes/miRs/proteins of your interest
Type the name of gene/miR/protein here:
Ex) TP53
Click Submit
I. Checking what clinical parameters are associated with
genes/miRs/proteins of your interest
Type the name of gene/miR/protein here:
Ex) TP53
Click Submit
Get to the summary page of TP53
I. Check what clinical parameters are associated with
genes/miRs/proteins of your interest
TP53 is associated with:
i) Race in breast cancer
ii) Triple marker in breast cancer
iii) N-Status in thyroid cancer
iv) Histo grade in uterine cancer
The mutation frequency of genes/miRs/proteins of your interest
across all cancer types
Sort function
The copy number variation frequency of genes/miRs/proteins of
your interest across all cancer types
I. What are the clinically relevant genes/miRs/proteins?
When you are interested in a certain cancer type, click here and select a cancer type
I. What are the clinically relevant genes/miRs/proteins?
If you select COADREAD, webpage shows the summary list with clinical parameters that are
available in COADREAD
I. What are the clinically relevant genes/miRs/proteins?
If you select genes in ClinicalStage, webpage shows the list of genes associated with a clinical stage in
COADREAD
I. What are the clinically relevant genes/miRs/proteins?
Clinical parameters with categorical values; click each class in a clinical parameter
I. What are the clinically relevant genes/miRs/proteins?
When you are interested in a clinical parameter, click here and select a clinical parameter
I. What are the clinically relevant genes/miRs/proteins?
If you select clinical stage, the web page shows the summary list from all the cancer types
currently in our data set where clinical stage is available. This is a pan-TCGA summary type
page.
I. What are the clinically relevant genes/miRs/proteins?
If you select genes in STAD, the web page shows the list of genes associated with a clinical stage in
stomach cancers
I. In summary, you can get to the summary page of WRN which is
associated with clinical stage in colorectal cancer three different ways
I. In summary, you can get to the summary page of WRN which is
associated with clinical stage in colorectal cancer by three different ways
II. Profiling by Clinical Parameter
When you want to know the differences of a gene between samples with different
clinical parameter types - in terms of genetic/proteomic profiling - use the middle
panel
How does PIK3CA behave differently between EBV infected and non-infected
samples in stomach cancer?
1. Type PIK3CA
2. Select STAD
3. Select EBV present
4. Click Submit
II. Profiling by Clinical Parameter
Summary of PIK3CA CNV between EBV infected and
non-infected samples in stomach cancer
II. Profiling by Clinical Parameter
Difference in PIK3CA mutations between EBV infected and non-infected samples in stomach cancer
II. Profiling by Clinical Parameter
Difference in expression level of PIK3CA between EBV infected and non-infected samples in stomach cancer
III. Two hit hypothesis test
What is the difference in copy number changes of TP53 between samples with and
without TP53 mutation in colorectal cancers?
Second level sample group:
With this example, it will then split colorectal cancers
into two groups –
i) samples with TP53 mutation
ii) samples without TP53 mutations
First level sample group:
With this example, what is the distribution of copy
number changes of TP53 in each group?
III. Testing two hit hypothesis
Summarize the copy number changes of TP53 by samples with/without TP53
mutations in colorectal cancers
III. Testing two hit hypothesis
Summarize the copy number changes of TP53 by samples with/without TP53
mutations in colorectal cancers
Hemizygous deletion occurred significantly more in samples with TP53 mutations than samples without
TP53 mutations

More Related Content

What's hot

Research aarkstore enterprise breast cancer therapies markets
Research aarkstore enterprise breast cancer therapies marketsResearch aarkstore enterprise breast cancer therapies markets
Research aarkstore enterprise breast cancer therapies marketsNeel Terde
 
American gut microbiome-2
American gut microbiome-2American gut microbiome-2
American gut microbiome-2JaclynW
 
Cell lines breast cancer-project
Cell lines breast cancer-project Cell lines breast cancer-project
Cell lines breast cancer-project Amitha Dasari
 
Michael's IUCRL Poster 2014 Close to Final with CDW edits
Michael's IUCRL Poster 2014 Close to Final with CDW editsMichael's IUCRL Poster 2014 Close to Final with CDW edits
Michael's IUCRL Poster 2014 Close to Final with CDW editsMichael Araya
 
Cell lines breast-project
Cell lines breast-projectCell lines breast-project
Cell lines breast-projectJaclynW
 
CAR-T Cell Products Validation
CAR-T Cell Products ValidationCAR-T Cell Products Validation
CAR-T Cell Products ValidationCreative-Biolabs
 
Pdx project
Pdx projectPdx project
Pdx projectJaclynW
 
Informa - Demonstrating Your PARP Inhibitor's Value
Informa - Demonstrating Your PARP Inhibitor's ValueInforma - Demonstrating Your PARP Inhibitor's Value
Informa - Demonstrating Your PARP Inhibitor's ValueDan Ngo
 
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
 
Asthma epigenomics
Asthma epigenomicsAsthma epigenomics
Asthma epigenomicsJaclynW
 
An Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsAn Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsCreative-Biolabs
 
Princewill pesentation seminar
Princewill pesentation seminarPrincewill pesentation seminar
Princewill pesentation seminarAmuda Tharheer
 
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer InstituteAARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer InstituteSubrata Chakravarty
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs
 

What's hot (19)

Research aarkstore enterprise breast cancer therapies markets
Research aarkstore enterprise breast cancer therapies marketsResearch aarkstore enterprise breast cancer therapies markets
Research aarkstore enterprise breast cancer therapies markets
 
American gut microbiome-2
American gut microbiome-2American gut microbiome-2
American gut microbiome-2
 
Cell lines breast cancer-project
Cell lines breast cancer-project Cell lines breast cancer-project
Cell lines breast cancer-project
 
PMED: APPM Workshop: Data & Analytics in Precision Oncology- Warren Kibbe, Ma...
PMED: APPM Workshop: Data & Analytics in Precision Oncology- Warren Kibbe, Ma...PMED: APPM Workshop: Data & Analytics in Precision Oncology- Warren Kibbe, Ma...
PMED: APPM Workshop: Data & Analytics in Precision Oncology- Warren Kibbe, Ma...
 
Michael's IUCRL Poster 2014 Close to Final with CDW edits
Michael's IUCRL Poster 2014 Close to Final with CDW editsMichael's IUCRL Poster 2014 Close to Final with CDW edits
Michael's IUCRL Poster 2014 Close to Final with CDW edits
 
Cell lines breast-project
Cell lines breast-projectCell lines breast-project
Cell lines breast-project
 
CAR-T Cell Products Validation
CAR-T Cell Products ValidationCAR-T Cell Products Validation
CAR-T Cell Products Validation
 
Pdx project
Pdx projectPdx project
Pdx project
 
Pdx project
Pdx project  Pdx project
Pdx project
 
Informa - Demonstrating Your PARP Inhibitor's Value
Informa - Demonstrating Your PARP Inhibitor's ValueInforma - Demonstrating Your PARP Inhibitor's Value
Informa - Demonstrating Your PARP Inhibitor's Value
 
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
 
Asthma epigenomics
Asthma epigenomicsAsthma epigenomics
Asthma epigenomics
 
2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders
 
Introducing ROSALIND
Introducing ROSALINDIntroducing ROSALIND
Introducing ROSALIND
 
An Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative BiolabsAn Overview of Pancreatic Cancer - Creative Biolabs
An Overview of Pancreatic Cancer - Creative Biolabs
 
Princewill pesentation seminar
Princewill pesentation seminarPrincewill pesentation seminar
Princewill pesentation seminar
 
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer InstituteAARSOTA Bio-Immunotherapy at Hope4Cancer Institute
AARSOTA Bio-Immunotherapy at Hope4Cancer Institute
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
 
KIYATEC-Advanced-CoCulture-LRes
KIYATEC-Advanced-CoCulture-LResKIYATEC-Advanced-CoCulture-LRes
KIYATEC-Advanced-CoCulture-LRes
 

Similar to 19

All you need to know about Biomarkers: Sept 2017 Webinar
All you need to know about Biomarkers: Sept 2017 WebinarAll you need to know about Biomarkers: Sept 2017 Webinar
All you need to know about Biomarkers: Sept 2017 WebinarFight Colorectal Cancer
 
Identification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesIdentification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesNuria Lopez-Bigas
 
Immunotherapy in endometrial
Immunotherapy in endometrialImmunotherapy in endometrial
Immunotherapy in endometrialOrmias Pratama
 
Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015Andreas Scherer
 
Cancer Gene Panels
Cancer Gene PanelsCancer Gene Panels
Cancer Gene PanelsGolden Helix
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentationoncolyticsinc
 
Deep learning-based cancer patient stratification
Deep learning-based cancer patient stratification Deep learning-based cancer patient stratification
Deep learning-based cancer patient stratification Altuna Akalin
 
The immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyThe immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyPaul D. Rennert
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentationVincenzo Esposito
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarFight Colorectal Cancer
 
A germline mutation in the brca1 3'utr predicts stage iv breast cancer
A germline mutation in the brca1 3'utr predicts stage iv breast cancerA germline mutation in the brca1 3'utr predicts stage iv breast cancer
A germline mutation in the brca1 3'utr predicts stage iv breast cancerDavid W. Salzman
 
Information about from where subjects will be recruited based on the.pdf
Information about from where subjects will be recruited based on the.pdfInformation about from where subjects will be recruited based on the.pdf
Information about from where subjects will be recruited based on the.pdffeelingsboutiques
 
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNABiomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNAFight Colorectal Cancer
 
10th european life science ceo forum
10th european life science ceo forum10th european life science ceo forum
10th european life science ceo forumtargovax2017
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsWarren Kibbe
 
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?Healthcare and Medical Sciences
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careAdonis Guancia
 

Similar to 19 (20)

All you need to know about Biomarkers: Sept 2017 Webinar
All you need to know about Biomarkers: Sept 2017 WebinarAll you need to know about Biomarkers: Sept 2017 Webinar
All you need to know about Biomarkers: Sept 2017 Webinar
 
brca mutation.pdf
brca mutation.pdfbrca mutation.pdf
brca mutation.pdf
 
Identification of cancer drivers across tumor types
Identification of cancer drivers across tumor typesIdentification of cancer drivers across tumor types
Identification of cancer drivers across tumor types
 
Immunotherapy in endometrial
Immunotherapy in endometrialImmunotherapy in endometrial
Immunotherapy in endometrial
 
Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015Web cast cancer gene panels march 11 2015
Web cast cancer gene panels march 11 2015
 
Cancer Gene Panels
Cancer Gene PanelsCancer Gene Panels
Cancer Gene Panels
 
April 2017 Corporate Presentation
April 2017 Corporate PresentationApril 2017 Corporate Presentation
April 2017 Corporate Presentation
 
Deep learning-based cancer patient stratification
Deep learning-based cancer patient stratification Deep learning-based cancer patient stratification
Deep learning-based cancer patient stratification
 
The immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyThe immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapy
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentation
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 Webinar
 
Biomarkers & Clinical Research
Biomarkers & Clinical ResearchBiomarkers & Clinical Research
Biomarkers & Clinical Research
 
A germline mutation in the brca1 3'utr predicts stage iv breast cancer
A germline mutation in the brca1 3'utr predicts stage iv breast cancerA germline mutation in the brca1 3'utr predicts stage iv breast cancer
A germline mutation in the brca1 3'utr predicts stage iv breast cancer
 
Information about from where subjects will be recruited based on the.pdf
Information about from where subjects will be recruited based on the.pdfInformation about from where subjects will be recruited based on the.pdf
Information about from where subjects will be recruited based on the.pdf
 
KIYATEC_Advanced_IO_CoCulture
KIYATEC_Advanced_IO_CoCultureKIYATEC_Advanced_IO_CoCulture
KIYATEC_Advanced_IO_CoCulture
 
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNABiomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
 
10th european life science ceo forum
10th european life science ceo forum10th european life science ceo forum
10th european life science ceo forum
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology Informatics
 
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?
Intra-Tumoral Lymphocytes in Breast Cancer: Real Perspectives?
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
 

19

  • 1. THE STANFORD-CANCER GENOME ATLAS PORTAL: A WEB/MOBILE NAVIGATION INTERFACE FOR EXPLORING THE CLINICAL ASSOCIATIONS OF CANCER DRIVERS Tutorial: How to navigate the web portal
  • 2. Three ways of looking TCGA data What are the clinically relevant genes/miRs/proteins? • By name of genes, miRs or proteins • By cancer type • By clinical parameters Profiling by clinical parameters: What is the difference in genetic/proteomic changes between classes in a clinical parameter in a certain cancer? Two hit hypothesis test: Do the two genetic/proteomic changes occur together or not? I II III
  • 3. I. Checking what clinical parameters are associated with genes/miRs/proteins of your interest Type the name of gene/miR/protein here: Ex) TP53 Click Submit
  • 4. I. Checking what clinical parameters are associated with genes/miRs/proteins of your interest Type the name of gene/miR/protein here: Ex) TP53 Click Submit Get to the summary page of TP53
  • 5. I. Check what clinical parameters are associated with genes/miRs/proteins of your interest TP53 is associated with: i) Race in breast cancer ii) Triple marker in breast cancer iii) N-Status in thyroid cancer iv) Histo grade in uterine cancer
  • 6. The mutation frequency of genes/miRs/proteins of your interest across all cancer types Sort function
  • 7. The copy number variation frequency of genes/miRs/proteins of your interest across all cancer types
  • 8. I. What are the clinically relevant genes/miRs/proteins? When you are interested in a certain cancer type, click here and select a cancer type
  • 9. I. What are the clinically relevant genes/miRs/proteins? If you select COADREAD, webpage shows the summary list with clinical parameters that are available in COADREAD
  • 10. I. What are the clinically relevant genes/miRs/proteins? If you select genes in ClinicalStage, webpage shows the list of genes associated with a clinical stage in COADREAD
  • 11. I. What are the clinically relevant genes/miRs/proteins? Clinical parameters with categorical values; click each class in a clinical parameter
  • 12. I. What are the clinically relevant genes/miRs/proteins? When you are interested in a clinical parameter, click here and select a clinical parameter
  • 13. I. What are the clinically relevant genes/miRs/proteins? If you select clinical stage, the web page shows the summary list from all the cancer types currently in our data set where clinical stage is available. This is a pan-TCGA summary type page.
  • 14. I. What are the clinically relevant genes/miRs/proteins? If you select genes in STAD, the web page shows the list of genes associated with a clinical stage in stomach cancers
  • 15. I. In summary, you can get to the summary page of WRN which is associated with clinical stage in colorectal cancer three different ways
  • 16. I. In summary, you can get to the summary page of WRN which is associated with clinical stage in colorectal cancer by three different ways
  • 17. II. Profiling by Clinical Parameter When you want to know the differences of a gene between samples with different clinical parameter types - in terms of genetic/proteomic profiling - use the middle panel How does PIK3CA behave differently between EBV infected and non-infected samples in stomach cancer? 1. Type PIK3CA 2. Select STAD 3. Select EBV present 4. Click Submit
  • 18. II. Profiling by Clinical Parameter Summary of PIK3CA CNV between EBV infected and non-infected samples in stomach cancer
  • 19. II. Profiling by Clinical Parameter Difference in PIK3CA mutations between EBV infected and non-infected samples in stomach cancer
  • 20. II. Profiling by Clinical Parameter Difference in expression level of PIK3CA between EBV infected and non-infected samples in stomach cancer
  • 21. III. Two hit hypothesis test What is the difference in copy number changes of TP53 between samples with and without TP53 mutation in colorectal cancers? Second level sample group: With this example, it will then split colorectal cancers into two groups – i) samples with TP53 mutation ii) samples without TP53 mutations First level sample group: With this example, what is the distribution of copy number changes of TP53 in each group?
  • 22. III. Testing two hit hypothesis Summarize the copy number changes of TP53 by samples with/without TP53 mutations in colorectal cancers
  • 23. III. Testing two hit hypothesis Summarize the copy number changes of TP53 by samples with/without TP53 mutations in colorectal cancers Hemizygous deletion occurred significantly more in samples with TP53 mutations than samples without TP53 mutations